Search details
1.
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
J Hepatol
; 78(1): 133-141, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36341767
2.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Lancet Oncol
; 23(1): 77-90, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34914889
3.
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(2): 200-208, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33972742
4.
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.
Br J Cancer
; 124(2): 407-413, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33071284
5.
Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial.
J Hepatol
; 74(3): 603-612, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33031846
6.
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
N Engl J Med
; 379(1): 54-63, 2018 Jul 05.
Article
in English
| MEDLINE | ID: mdl-29972759
7.
Varices on computed tomography as predictor of survival after hepatic resection in patients with single hepatocellular carcinoma.
J Gastroenterol Hepatol
; 36(1): 225-232, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-32453898
8.
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
J Hepatol
; 73(6): 1460-1469, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32710922
9.
Synthesis and Cytotoxicity Studies of Bioactive Benzofurans from Lavandula agustifolia and Modified Synthesis of Ailanthoidol, Homoegonol, and Egonol.
J Nat Prod
; 83(11): 3354-3362, 2020 11 25.
Article
in English
| MEDLINE | ID: mdl-33073572
10.
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
Gut
; 68(6): 1065-1075, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30108162
11.
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
J Hepatol
; 70(4): 684-691, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30529387
12.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet
; 391(10126): 1163-1173, 2018 03 24.
Article
in English
| MEDLINE | ID: mdl-29433850
13.
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Invest New Drugs
; 37(3): 567-572, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30523474
14.
Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study.
J Med Virol
; 90(10): 1593-1603, 2018 10.
Article
in English
| MEDLINE | ID: mdl-29900560
15.
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
J Hepatol
; 66(6): 1166-1172, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28131794
16.
A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score.
J Gastroenterol Hepatol
; 32(3): 651-658, 2017 Mar.
Article
in English
| MEDLINE | ID: mdl-27519171
17.
Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.
Br J Cancer
; 124(9): 1611, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33531694
18.
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.
J Hepatol
; 65(2): 289-95, 2016 08.
Article
in English
| MEDLINE | ID: mdl-27085251
19.
The role of hepatic resection in the treatment of hepatocellular cancer.
Hepatology
; 62(2): 440-51, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-25678263
20.
Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
Antimicrob Agents Chemother
; 59(2): 972-8, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25421484